MAPT and Alzheimer disease: We then compared the performance of the GM network markers with two other biomarkers known to be associated with the decline in prodromal Alzheimer’s disease [i.e. HV and CSF phosphorylated-tau (p-tau) levels],11,12 and determined an optimal model for detecting fast progressors.